Iterum Therapeutics plc
NASDAQ: ITRM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Corey N. Fishman
- Employees
- 9
- Headquarters
- Dublin, Ireland
- IPO year
- 2018
- Market cap
- $1.6M
- Website
- https://www.iterumtx.com
Loading ITRM…
Loading profile data…Frequently asked questions about ITRM
What does Iterum Therapeutics plc (ITRM) do?
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formul...
Where does ITRM trade?
Iterum Therapeutics plc (ITRM) trades on the NASDAQ Capital Market.
What sector is ITRM in?
Iterum Therapeutics plc (ITRM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Iterum Therapeutics plc?
Corey N. Fishman is the chief executive officer of Iterum Therapeutics plc (ITRM).
Where is Iterum Therapeutics plc headquartered?
Iterum Therapeutics plc is headquartered in Ireland.
Does ITRM pay a dividend?
Iterum Therapeutics plc (ITRM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ITRM go public?
Iterum Therapeutics plc (ITRM) completed its initial public offering in 2018.